Core Revision
Revision aid, not clinical advice. This page is educational material written for exam preparation. It is not a substitute for the current guideline or for clinical judgement, and must not be relied on for the care of any individual. Always check up-to-date national guidance and verify independently before acting on anything here.
PCOS is now PMOS — what changed, why, and what NICE’s new guideline will ask
Dr Victoria HammondCo-Founder & Lead for Educational Design · 8 min read
Published 17 August 2026 · Checked against sources 28 September 2026
After more than a decade, roughly 22,000 stakeholders and three global surveys, polycystic ovary syndrome has a new name. Since May 2026, a global consensus published in The Lancet has renamed the condition formerly known as PCOS PMOS — polyendocrine metabolic ovarian syndrome — and NICE has consulted on the first dedicated UK national guideline for it, due in December 2026. This is exactly the kind of change exam writers love: a rename that isn’t cosmetic, sitting on top of real shifts in who gets investigated and how they’re monitored.
Core Lens
PCOS to PMOS, in six points
- A new name. An international consensus published in The Lancet in May 2026 renamed PCOS polyendocrine metabolic ovarian syndrome (PMOS), putting its hormonal and metabolic features first.
- Still a NICE draft. Consultation on NICE’s PMOS guideline closed on 11 August 2026 and publication is expected in December 2026, so expect exam stems to say PCOS for some time.
- A wider net. The draft recommends suspecting PMOS from age 10 with irregular or absent periods, or with signs of excess androgens even when periods are regular.
- An annual review. The draft recommends offering people aged 10 and over diagnosed with PMOS an annual review of symptoms, medicines and long-term risks such as diabetes and cardiovascular disease.
- Off-label medicines. The draft marks some uses of progestogens, combined oral contraceptives, spironolactone and metformin as off-label, and says spironolactone needs effective contraception because of its teratogenic potential.
- For the exam. The pattern is one condition under two names, whose metabolic and cardiovascular risks explain the annual review, whether a stem says PCOS or PMOS.
Revision aid, not clinical advice — checked against NICE’s draft PMOS guideline (GID-NG10436) on 28 September 2026.
You are reading the Core Lens — the points that matter. Open the Deep Dive for the full article.
Sitting the AKT? Try twenty questions free.
Twenty original AKT questions in the exam's 80/10/10 split: sixteen clinical, two on evidence-based practice and two on organisation and management, with the reasoning after every one and a marked report. Free, no card and the first five are open to all.
Here’s what actually changed, why the profession decided the old name was doing harm, and where the marks are likely to hide.
Why “polycystic ovary syndrome” had to go
The rename was led by Professor Helena Teede at Monash University on behalf of a Global Name Change Consortium, spanning more than 50 patient and professional organisations. The process ran from 2015 to 2026, gathered input from around 22,000 clinicians, researchers, patients and charities across three major surveys (2017, 2023 and 2025), and finished with a vote in which 87 of 90 international panel members backed adopting the new name immediately. The consensus was published in The Lancet.
The problem with the old name was baked into the words themselves. As Professor Teede put it, “there is actually no increase in abnormal cysts” on the ovaries in this condition — what looks like a string of cysts on ultrasound is really a normal population of small, immature follicles. Calling the condition “polycystic ovary syndrome” told patients and clinicians it was a gynaecological disease of the ovaries, when it’s really a whole-body hormonal and metabolic condition that happens to also affect the ovaries. That mismatch had real consequences: patients without visible ovarian changes were sometimes dismissed despite clear metabolic or androgenic symptoms, and patients with ovarian cysts for unrelated reasons assumed they had PCOS when they didn’t. The WHO estimates that up to 70% of people with the condition are undiagnosed and that it affects 10–13% of women of reproductive age; the consortium puts that at about 1 in 8, or more than 170 million people worldwide.
Everything in this update flows from one reclassification: PMOS has moved from being framed as an ovarian disease to being framed as a whole-body endocrine-metabolic condition that also affects the ovaries. Once you hold that idea, the wider diagnostic net, the annual metabolic and cardiovascular monitoring, and the extension of who should be assessed for it all follow logically — they’re not separate changes, they’re the same change applied consistently.
What NICE’s draft guideline actually says
NICE’s guideline (project reference GID-NG10436) is the first dedicated UK national guidance for this condition. It’s still in draft: public consultation ran from 1 July to 11 August 2026, and final publication is expected on 9 December 2026. Three things stand out for practice — and for the exam.
Who to investigate
NICE recommends suspecting PMOS, and investigating, in anyone aged 10 and over presenting with irregular or absent periods, or symptoms and signs of excess androgen levels (such as hirsutism or acne). Crucially, the draft widens who this applies to: it says not to exclude the possibility of PMOS in women, trans men and non-binary people who have experienced menopause (its scope covers trans men and non-binary people aged 18 and over who have not had gender-affirming hormones or surgery). It also notes the condition may be more prevalent in women of Black, Asian and mixed ethnicity, and asks clinicians to factor that into how they assess symptoms.
Annual review for everyone diagnosed
For the first time, NICE recommends that an annual review be offered to every patient diagnosed with PMOS, covering: current symptoms (menstrual irregularity, hirsutism), medication and treatment review, and screening for the long-term risks the condition carries — principally type 2 diabetes and cardiovascular disease. The broader evidence base behind the guideline also links PMOS to obstructive sleep apnoea, non-alcoholic fatty liver disease, mental health conditions, and pregnancy complications such as gestational diabetes and pre-eclampsia.
Management the draft sets out
The draft guidance is explicit that several of the treatments used are off-label, which is itself worth knowing for the exam:
- Menstrual irregularity: off-label progestogens.
- Hirsutism: off-label combined oral contraceptives or spironolactone — spironolactone requires effective contraception because of its teratogenic risk.
- Metabolic health: off-label metformin.
- Weight management: the guidance recognises weight gain is a genuine challenge in PMOS, but advises against weight-loss medications for fertility treatment outside a research setting.
- Fertility treatment: specific guidance is provided, though detail remains limited at this draft stage.
A guideline that renames a condition and widens its diagnostic criteria is a gift to exam writers, because it tests whether you’ve kept up. Watch for:
- The name itself. Expect stems to start using “PMOS” — don’t let an unfamiliar acronym cost you time recognising a familiar clinical picture.
- “No cysts on ultrasound, so it can’t be PCOS/PMOS.” This is now explicitly the wrong instinct. Ovarian cysts were never required for diagnosis, and the rename exists partly to correct the assumption that they are.
- “Diagnosed years ago, no follow-up since.” A stem like this is now testing whether you know an annual review — symptoms, medication, T2DM and cardiovascular risk — is recommended for everyone diagnosed, not just those who ask.
- Trans and non-binary patients. A stem describing a trans man or non-binary patient with oligomenorrhoea and hyperandrogenism is testing whether you exclude PMOS purely on gender identity grounds — NICE says you shouldn’t.
- Spironolactone for hirsutism. The trap is prescribing it without first confirming effective contraception, given its teratogenic risk.
- Type 2 diabetes — insulin resistance is common in PMOS; screen at annual review.
- Cardiovascular disease — part of the same metabolic risk profile the rename was designed to foreground.
- Obstructive sleep apnoea and non-alcoholic fatty liver disease — easy to miss if you’re still thinking of this as a purely gynaecological condition.
- Mental health — anxiety, depression and disordered eating are all recognised comorbidities worth asking about directly.
- Pregnancy complications — gestational diabetes and pre-eclampsia risk should shape pre-conception counselling.
Terminology changes like this one can feel unsettling this close to an exam — you learn a name, a set of criteria, an acronym, and then it moves. Try not to let the new label become one more thing to panic-memorise on its own. Anchor it to the clinical logic instead: this isn’t a new disease, it’s the same condition being described more accurately, with monitoring that now matches what we’ve known about the metabolic and cardiovascular risk for years. If you understand why the annual review exists, you’ll answer the question correctly whether the stem says PCOS or PMOS.
Dr Victoria Hammond · MBBS, BSc (Hons)
What to do with this before your exam
- Learn the new name and what it stands for: PMOS — polyendocrine metabolic ovarian syndrome. Expect exam stems to start using it.
- Drop “cysts required” thinking: a normal ovarian ultrasound does not rule out PMOS.
- Know who to investigate: age 10+, irregular/absent periods and/or signs of excess androgens — and a stem may test that menopause does not rule PMOS out (the draft says so for women, trans men and non-binary people).
- Carry the annual review: symptoms, medication review, and screening for T2DM and cardiovascular risk, offered to everyone diagnosed.
- Hold the off-label treatments and their caveats: progestogens for menstrual irregularity; COC or spironolactone (with effective contraception) for hirsutism; metformin for metabolic health.
That’s five facts. They’re also, not coincidentally, the five things a well-written exam stem about this topic is most likely to be testing.
Sources & currency. This summary reflects the global rename consensus published in The Lancet (May 2026) and NICE’s draft guideline GID-NG10436, “Polyendocrine Metabolic Ovarian Syndrome (PMOS)”, open for public consultation 1 July–11 August 2026 with final publication expected 9 December 2026 — current at the time of writing (August 2026). Until NICE’s guideline is finalised, UK practice continues to draw on the 2023 international evidence-based guideline (led by Monash University), and a three-year global transition period to the new terminology runs from 2026, with full adoption expected at the 2028 international guideline update — so “PCOS” will keep appearing in older material, patient conversations and possibly exam stems for a while yet. Guidance evolves — always check the live NICE guideline before applying it to a patient or relying on it in your exam. A revision aid, not a substitute for the full guideline or your own clinical judgement.
Written by practising UK GPs — Dr Victoria Hammond and Dr David Palethorpe. Education only — always confirm against current guidance. Core Revision is an independent revision resource.
